Racial & Ethnic minority Acceleration Consortium for Health Equity (REACH) Response from Indigenous Innovators Collaborative

种族

• 批准号: 10897463
• 负责人: Billie Kipp
• 金额: $ 32.5万
• 依托单位: AMERICANS FOR INDIAN OPPORTUNITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-05 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10897463
• 关键词: Racial; Ethnic; minority; Acceleration; Consortium

Project Summary/Abstract 30 lines of text With a collaborative approach grounded in Indigenous core cultural values, the Indigenous Innovators Collaborative (IIC) team will engage in community-based participatory research study to address the FDA priorities as outlined in FDA OMHHE Health Equity Innovation Award: Racial and Ethnic Minority Acceleration Consortium for Health Equity (REACH) funding opportunity. The IIC seeks to engage American Indian and Alaska Native (AIAN) communities, stakeholders, researchers in an exploration of clinical trials and promote cultural knowledge in understanding clinical trials in Indian Country. The IIC consists of core partners that form the Administrative Core (AC) of this project, including: (1) Americans for Indian Opportunity (AIO), which serves as the fiscal agent/grant administrator; (2) Co-Investigator 1: Dr. Myra Parker (Three Affiliated Tribes), University of Washington; (3) Co-Investigator 2: Dr. Billie Jo Kipp (Blackfeet), Natives in Philanthropy; (4) Principle Investigator: Stephine Poston (Pueblo of Sandia), Poston & Associates, LLC; and, (5) the United Tribes Technical College (UTTC), an accredited, land-grant tribal college located in Bismarck, North Dakota, that serves the five reservations in ND and tribal members across the U.S. UTTC has provided higher education support to over 10,000 AI students from over 75 tribes. We propose to expand this effort to implement an exploratory study that would employ a mixed methods approach to improve understandings of AIAN perceptions of clinical trials and gene therapy across multiple regions of the U.S. Our aims include: 1. Specific Aim 1 – Partner with local tribal colleges to assess AIAN community knowledge, concerns, and beliefs about clinical trials and gene therapy within the 12 IHS regions using a mixed methods approach. a. Hypothesis 1 – AIAN community knowledge, concerns, and beliefs about clinical trials and gene therapy will vary across IHS regions and will reflect local tribal cultural understandings. 2. Specific Aim 2 – Identify barriers and supports for clinical trials and gene therapy among AIAN within the 12 IHS regions by collecting qualitative data from AIAN providers, researchers, and public health experts. a. Hypothesis 2 – Barriers and supports for clinical trials and gene therapy among AIAN will vary by IHS Region and tribal cultures.

项目摘要/摘要30行文本 以土著核心文化价值观为基础的合作方式，土著人民 创新者协作(IIC)团队将参与基于社区的参与性研究 FDA OMHHE健康公平创新奖中概述的FDA优先事项的研究： 种族和少数民族促进健康公平联盟(REACH)资金 机会。IIC寻求与美国印第安人和阿拉斯加原住民(AIAN)社区接触， 利益相关者、研究人员探索临床试验并促进文化知识在 了解印度国家的临床试验。国际投资委员会由核心合作伙伴组成，组成 该项目的行政核心(AC)，包括：(1)美国人争取印度机会(AIO)， 担任财务代理/赠款管理人；(2)合作调查员1：迈拉·帕克博士 (三个附属部落)，华盛顿大学；(3)合作调查员2：Billie Jo Kipp博士 (4)首席调查员：斯蒂芬·波斯顿(Pueblo of Sandia)，Poston&Associates，LLC；以及，(5)联合部落技术学院(UTTC)，以及 位于北达科他州俾斯麦的经认可的赠与土地的部落学院，为五人提供服务 UTTC在美国各地保留了ND和部落成员，提供了高等教育 支持来自75多个部落的10,000多名人工智能学生。我们建议将这一努力扩大到 实施探索性研究，采用混合方法改进 AIAN对临床试验和基因治疗多个地区的理解 美国的目标包括： 1.具体目标1--与当地部落学院合作评估AIAN社区 12个IHS中关于临床试验和基因治疗的知识、关注和信念 区域使用混合方法的方法。 A.假设1-AIAN社区对临床的知识、关注和信念 试验和基因治疗将在IHS地区有所不同，并将反映当地部落 文化理解。 2.具体目标2--确定临床试验和基因治疗的障碍和支持 通过收集AIAN的定性数据，在12个IHS区域内的AIAN之间 提供者、研究人员和公共卫生专家。 A.假设2--临床试验和基因疗法的障碍和支持 AIAN将根据IHS地区和部落文化的不同而不同。